Papers associated with head (and kcnh2)

Limit to papers also referencing gene:
Show all head papers

???pagination.result.count???

???pagination.result.page??? 1 2 3 ???pagination.result.next???

Sort Newest To Oldest

Sort Oldest To Newest

	Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer., Levin M., Cell. April 15, 2021;
	Polyunsaturated fatty acid analogues differentially affect cardiac NaV, CaV, and KV channels through unique mechanisms., Bohannon BM., Elife. March 24, 2020; 9
	Toward a Structural View of hERG Activation by the Small-Molecule Activator ICA-105574., Zangerl-Plessl EM., J Chem Inf Model. January 27, 2020; 60 (1): 360-371.
	Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel., Vasseur L., Toxicon X. February 23, 2019; 2 100010.
	Design and Synthesis of Novel Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors with the Ability To Rescue Auditory Gating Deficit in Mice., Li Y., J Med Chem. January 10, 2019; 62 (1): 159-173.
	Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3., Gardner A., Mol Pharmacol. October 1, 2017; 92 (4): 437-450.
	Regulation of human cardiac potassium channels by full-length KCNE3 and KCNE4., Abbott GW., Sci Rep. December 6, 2016; 6 38412.
	Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium., Pedersen PJ., PLoS One. September 4, 2015; 10 (9): e0138320.
	Stoichiometry of altered hERG1 channel gating by small molecule activators., Wu W., J Gen Physiol. April 1, 2014; 143 (4): 499-512.
	VEGFA-dependent and -independent pathways synergise to drive Scl expression and initiate programming of the blood stem cell lineage in Xenopus., Ciau-Uitz A., Development. June 1, 2013; 140 (12): 2632-42.
	Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate., Dong Q., Biol Pharm Bull. January 1, 2013; 36 (2): 268-75.
	Kcnh1 voltage-gated potassium channels are essential for early zebrafish development., Stengel R., J Biol Chem. October 12, 2012; 287 (42): 35565-35575.
	Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channels., Twiner MJ., Chem Res Toxicol. September 17, 2012; 25 (9): 1975-84.
	Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule., Garg V., J Gen Physiol. September 1, 2012; 140 (3): 307-24.
	A molecular switch driving inactivation in the cardiac K+ channel HERG., Köpfer DA., PLoS One. January 1, 2012; 7 (7): e41023.
	Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide., Garg V., Mol Pharmacol. October 1, 2011; 80 (4): 630-7.
	Sig1R protein regulates hERG channel expression through a post-translational mechanism in leukemic cells., Crottès D., J Biol Chem. August 12, 2011; 286 (32): 27947-58.
	Recombinant expression of the toxic peptide ErgTx1 and role of Met35 on its stability and function., Jimenez-Vargas JM., Peptides. March 1, 2011; 32 (3): 560-7.
	Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels., Larsen AP., Br J Pharmacol. October 1, 2010; 161 (3): 614-28.
	Response of i(kr) and HERG currents to the antipsychotics tiapride and sulpiride., Jo SH., Korean J Physiol Pharmacol. October 1, 2010; 14 (5): 305-10.
	Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine., Obers S., Naunyn Schmiedebergs Arch Pharmacol. May 1, 2010; 381 (5): 385-400.
	Inhibition of the human ether-a-go-go-related gene (HERG) K+ channels by Lindera erythrocarpa., Hong HK., J Korean Med Sci. December 1, 2009; 24 (6): 1089-98.
	H(1) antihistamine drug promethazine directly blocks hERG K(+) channel., Jo SH., Pharmacol Res. November 1, 2009; 60 (5): 429-37.
	Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors., Mosley CA., Bioorg Med Chem. September 1, 2009; 17 (17): 6463-80.
	Characterization of novel KCNH2 mutations in type 2 long QT syndrome manifesting as seizures., Keller DI., Can J Cardiol. August 1, 2009; 25 (8): 455-62.
	Differential modulation of cardiac potassium channels by Grb adaptor proteins., Ureche ON., Biochem Biophys Res Commun. June 19, 2009; 384 (1): 28-31.
	Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes., Mruk K., PLoS One. January 1, 2009; 4 (1): e4236.
	Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents., Scherer D., Br J Pharmacol. January 1, 2009; 156 (2): 226-36.
	The effects of chiral isolates of methadone on the cardiac potassium channel IKr., Lin C., Cardiology. January 1, 2009; 113 (1): 59-65.
	Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation., Barrows B., Channels (Austin). January 1, 2009; 3 (4): 239-48.
	Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration., Kim YJ., J Cardiovasc Pharmacol. December 1, 2008; 52 (6): 485-93.
	[Analysis and analyzing mechanisms of HERG channel kinetics]., Wang X., Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. October 1, 2008; 25 (5): 1068-73.
	Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652., Jo SH., Eur J Pharmacol. September 11, 2008; 592 (1-3): 19-25.
	Characterization of hERG1a and hERG1b potassium channels-a possible role for hERG1b in the I (Kr) current., Larsen AP., Pflugers Arch. September 1, 2008; 456 (6): 1137-48.
	Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes., Tu DN., Acta Pharmacol Sin. August 1, 2008; 29 (8): 913-22.
	Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin., Scherer D., Naunyn Schmiedebergs Arch Pharmacol. July 1, 2008; 378 (1): 73-83.
	Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243)., Xu X., Mol Pharmacol. June 1, 2008; 73 (6): 1709-21.
	Gambierol, a toxin produced by the dinoflagellate Gambierdiscus toxicus, is a potent blocker of voltage-gated potassium channels., Cuypers E., Toxicon. May 1, 2008; 51 (6): 974-83.
	Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling., Tseng GN., Biophys J. May 15, 2007; 92 (10): 3524-40.
	Upregulation of KCNE1 induces QT interval prolongation in patients with chronic heart failure., Watanabe E., Circ J. April 1, 2007; 71 (4): 471-8.
	Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant., Hosaka Y., Channels (Austin). January 1, 2007; 1 (3): 198-208.
	Blockade of HERG human K+ channel and IKr of guinea pig cardiomyocytes by prochlorperazine., Kim MD., Eur J Pharmacol. August 21, 2006; 544 (1-3): 82-90.
	[Electrophysiological characterization of long QT syndrome associated mutations V630A and N633S]., She HR., Zhonghua Xin Xue Guan Bing Za Zhi. June 1, 2006; 34 (6): 523-7.
	Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels., Kiesecker C., Naunyn Schmiedebergs Arch Pharmacol. June 1, 2006; 373 (3): 212-20.
	Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels., Clarke CE., J Physiol. June 1, 2006; 573 (Pt 2): 291-304.
	Molecular determinants of HERG channel block., Kamiya K., Mol Pharmacol. May 1, 2006; 69 (5): 1709-16.
	Chemical modification of the human ether-a-go-go-related gene (HERG) K+ current by the amino-group reagent trinitrobenzene sulfonic acid., Jo SH., Arch Pharm Res. April 1, 2006; 29 (4): 310-7.
	Inhibition of cardiac HERG potassium channels by antidepressant maprotiline., Ferrer-Villada T., Eur J Pharmacol. February 15, 2006; 531 (1-3): 1-8.
	Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs., Perry M., Mol Pharmacol. February 1, 2006; 69 (2): 509-19.
	Mechanism of action of a novel human ether-a-go-go-related gene channel activator., Casis O., Mol Pharmacol. February 1, 2006; 69 (2): 658-65.

???pagination.result.page??? 1 2 3 ???pagination.result.next???